AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $80.10.

A number of research analysts recently issued reports on ANAB shares. HC Wainwright restated a “buy” rating and set a $66.00 price objective on shares of AnaptysBio in a research report on Monday. Wall Street Zen cut AnaptysBio from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. UBS Group boosted their price target on shares of AnaptysBio from $70.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Wedbush upped their price target on shares of AnaptysBio from $60.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Finally, Truist Financial raised shares of AnaptysBio to a “hold” rating in a report on Wednesday, March 25th.

AnaptysBio Stock Up 0.1%

Shares of NASDAQ ANAB opened at $55.46 on Wednesday. The firm’s 50-day moving average price is $55.67 and its two-hundred day moving average price is $44.24. AnaptysBio has a 52-week low of $15.40 and a 52-week high of $68.39. The stock has a market capitalization of $1.59 billion, a P/E ratio of -106.65 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.89 by $0.69. The company had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. As a group, equities research analysts expect that AnaptysBio will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has initiated a share repurchase plan on Friday, March 27th that permits the company to buyback $100,000.00 billion in shares. This buyback authorization permits the biotechnology company to purchase up to 5,352,316.2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In other news, insider Paul F. Lizzul sold 3,650 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total transaction of $163,191.50. Following the completion of the transaction, the insider directly owned 42,088 shares in the company, valued at approximately $1,881,754.48. The trade was a 7.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Magda Marquet sold 11,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $48.23, for a total value of $530,530.00. Following the completion of the transaction, the director directly owned 9,930 shares of the company’s stock, valued at $478,923.90. This trade represents a 52.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 110,193 shares of company stock valued at $5,333,138 in the last ninety days. Insiders own 33.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC grew its stake in shares of AnaptysBio by 1.5% in the fourth quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company’s stock worth $732,000 after purchasing an additional 225 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of AnaptysBio by 24.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 263 shares during the period. Larson Financial Group LLC raised its stake in shares of AnaptysBio by 21.2% during the fourth quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company’s stock valued at $79,000 after purchasing an additional 284 shares in the last quarter. Susquehanna Portfolio Strategies LLC lifted its holdings in AnaptysBio by 1.4% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company’s stock worth $1,743,000 after purchasing an additional 500 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.